Display options
Cite
Touloumis Z, Delis SG, Triantopoulou C, et al. Primary hepatic carcinoid; a diagnostic dilemma: a case report. Cases J. 2008;1(1):314doi: 10.1186/1757-1626-1-314.
Touloumis, Z., Delis, S. G., Triantopoulou, C., Giannakou, N., Avgerinos, C., & Dervenis, C. (2008). Primary hepatic carcinoid; a diagnostic dilemma: a case report. Cases journal, 1(1), 314. https://doi.org/10.1186/1757-1626-1-314
Touloumis, Zisis, et al. "Primary hepatic carcinoid; a diagnostic dilemma: a case report." Cases journal vol. 1,1 (2008): 314. doi: https://doi.org/10.1186/1757-1626-1-314
Touloumis Z, Delis SG, Triantopoulou C, Giannakou N, Avgerinos C, Dervenis C. Primary hepatic carcinoid; a diagnostic dilemma: a case report. Cases J. 2008 Nov 17;1(1):314. doi: 10.1186/1757-1626-1-314. PMID: 19014620; PMCID: PMC2596793.
Copy Download .nbib Format: NLM
Share it on

Cases J. 2008 Nov 17;1(1):314. doi: 10.1186/1757-1626-1-314.

Primary hepatic carcinoid; a diagnostic dilemma: a case report.

Cases journal

Zisis Touloumis, Spiros G Delis, Charikleia Triantopoulou, Nikoletta Giannakou, Costas Avgerinos, Christos Dervenis

Affiliations

  1. Liver Surgical Unit, First Department of Surgery, "Agia Olga" General Hospital, 3-5 Agias Olgas street, 14233 N, Ionia, Athens, Greece. [email protected].

PMID: 19014620 PMCID: PMC2596793 DOI: 10.1186/1757-1626-1-314

Abstract

INTRODUCTION: Primary hepatic carcinoid tumours (PHCTs) are extremely rare neuroendocrine neoplasms. Only 58 cases have been reported in the literature and less than 10 cases were functional.

CASE PRESENTATION: We present a case of a 65 years old, Caucasian female with a large unresectable primary hepatic carcinoid tumor secreting 5-hydroxyindoleacetic acid (5-HIAA), presented with flushing and diarrhoea and treated with trans-catheter arterial embolization (TACE) and subsequent administration of lanreotide (long acting somatostatin analogue).

CONCLUSION: The diagnosis of PHCTs is difficult due to their common radiologic characteristics with other liver lesions. Their diagnosis is based on the exclusion of other sites of disease and the histologic confirmation. Although the mainstay of treatment when is technically feasible is surgical resection with optimal 5-year survival and low recurrence rate, in cases of unresectable disease palliation with combination of TACE and administration of somatostatin analogues have good results in controlling the disease and the patients symptoms.

References

  1. Am J Clin Pathol. 1988 Apr;89(4):561-4 - PubMed
  2. Ann Surg Oncol. 2003 Dec;10(10):1171-5 - PubMed
  3. J Clin Gastroenterol. 1996 Jul;23(1):60-2 - PubMed
  4. Br J Radiol. 1999 Feb;72(854):207-9 - PubMed
  5. Ann Surg. 2004 Feb;239(2):210-9 - PubMed
  6. Surgery. 1988 Dec;104(6):1080-9 - PubMed
  7. Hepatogastroenterology. 1999 Jul-Aug;46(28):2547-50 - PubMed
  8. Ann Surg. 1999 Jun;229(6):815-21; discussion 822-3 - PubMed
  9. J Clin Oncol. 1987 Oct;5(10):1502-22 - PubMed
  10. J Clin Ultrasound. 2005 Jul-Aug;33(6):302-4 - PubMed
  11. J Comput Assist Tomogr. 1992 Jan-Feb;16(1):99-102 - PubMed
  12. Ann Surg. 1987 Aug;206(2):115-25 - PubMed
  13. Ann Nucl Med. 2005 Oct;19(7):611-5 - PubMed
  14. World J Surg. 1996 Feb;20(2):147-56 - PubMed

Publication Types